Astrazeneca Pharma India Ltd (ASTRAZEN) — shareholding pattern, promoter holding, financials and share price
About Astrazeneca Pharma India Ltd (ASTRAZEN)
Astrazeneca Pharma India Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ASTRAZEN and on the BSE under scrip code 506820. Its ISIN is INE203A01020.
AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products. [1]
AstraZeneca Pharma India Limited (APIL) is a subsidiary engaged in manufacturing, distributing, and marketing pharmaceutical products, focusing on therapeutic areas like oncology, cardio metabolic, and respiratory care.
The company has aligned with AstraZeneca PLC’s global therapeutic focus, driving significant market presence in India’s diabetes and cardiovascular segments through strategic partnerships and product launches.
Listed peers in Pharmaceuticals: Granules India Ltd, Pfizer Ltd, ERIS Lifesciences Ltd, Caplin Point Laboratories Ltd, OneSource Specialty Pharma Ltd, Natco Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹8,131.95 a share on 10 Jul 2026, Astrazeneca Pharma India Ltd (ASTRAZEN) was valued at a price-to-earnings ratio of 108.41x against an industry P/E of 36.41x and a price-to-book of 26.39x on a book value of ₹308.14 per share as of Mar 2025. Solomo computes return on equity of 24.34% and return on capital employed of 31.84% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 108.41x
- Industry P/E
- 36.41x
- P/B
- 26.39x
- EPS (TTM)
- ₹75.01
- Book value / share
- ₹308.14
- ROE
- 24.34%
- ROCE
- 31.84%
- ROA
- 12.35%
- Debt / equity
- 0.05x
- Dividend yield
- 0.4%
- EBITDA margin
- 12.54%
- 52-week range
- ₹7,630 – ₹9,850
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Astrazeneca Pharma India Ltd (ASTRAZEN) reported revenue of ₹2,276 crore, net profit of ₹188 crore and earnings per share of ₹75.01. That compares with revenue of ₹1,716 crore and net profit of ₹116 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹579 crore and net profit ₹45 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 806 | 1,003 | 1,296 | 1,716 | 2,276 |
| Net profit (₹ cr) | 62 | 99 | 162 | 116 | 188 |
| EPS (₹) | 24.64 | 39.72 | 64.6 | 46.3 | 75.01 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 13.03% | 15.59% | 28.67% | 32.48% |
| Profit growth | 40.99% | 9.89% | 23.40% | -28.34% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 75% of Astrazeneca Pharma India Ltd (ASTRAZEN) (unchanged from the previous quarter), foreign institutional investors (FII) hold 2.68% and domestic institutional investors (DII) hold 6.08%. Market capitalisation was ₹20,330 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMALL CAP FUND(VARIOUS SCHEMES) 2.89%, TEJAS BHALCHANDRA TRIVEDI 2.68%, SHIVANI TEJAS TRIVEDI 2.33%, ICICI PRUDENTIAL - VARIOUS SCHEMES 1.39%, BANDHAN - VARIOUS SCHEMES 1.28%, PRASHANT JAIN 1.1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 75% | - | 2.68% | 6.08% | 25% |
| Mar 2026 | 75% | - | 2.78% | 5.8% | 25% |
| Dec 2025 | 75% | - | 2.71% | 5.56% | 25% |
| Sep 2025 | 75% | - | 2.74% | 5.26% | 25% |
| Jun 2025 | 75% | - | 3.03% | 4.56% | 25% |
| Mar 2025 | 75% | - | 2.89% | 4.65% | 25% |
| Dec 2024 | 75% | - | 2.93% | 5.22% | 25% |
| Sep 2024 | 75% | - | 2.9% | 5.1% | 25% |